Strategic collaborations are at the core of our business, whether we out-license our PharmFilm® technology to reinvent medicines or in-license adjacent assets for development and commercialization. Aquestive partners to solve tough clinical and business challenges. We offer industry-leading scientific and regulatory expertise, integrated capabilities to test and deliver treatments, and best-in-class efficiency to get new solutions to patients.
proprietary and pipeline collaborations
A foundation in CNS
Commercialization expertise across therapeutic areas
Aquestive is interested in assets that are complementary to our existing pipeline products in CNS, although we will consider products that meet our criteria in adjacent therapy areas. Typically, we look to in-license products for which most of the clinical trials have been conducted and that are either in the process of registration or are already registered and ready to commercialize. Our assessment processes for in-licensing opportunities are led by our business development team, supported by expertise from other functional areas of the business.
Aquestive’s collaborators commercialize hundreds of millions of doses of PharmFilm® every year. We collaborate to deliver novel molecules in clinical development and to repurpose approved medications for the benefit of patients and caregivers. Aquestive maintains a robust and fully integrated infrastructure for managing projects from inception to commercial supply.
to meet unmet needs
Aquestive and Indivior jointly developed SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in less than 4 years. The market leader for 8 years, SUBOXONE® has never experienced an out-of-stock occurrence.
We work with collaborators to help determine the best techniques and processes for reformulating proven molecules on film, and we share our expertise across the continuum of development activities.